CounterPath (NASDAQ:CPAH) Upgraded to Buy at ValuEngine

CounterPath (NASDAQ:CPAH) (TSE:CCV) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday, ValuEngine reports.

CPAH stock traded down $0.03 during trading on Thursday, reaching $1.48. 17,800 shares of the stock were exchanged, compared to its average volume of 114,518. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a 50 day simple moving average of $1.52. CounterPath has a 1 year low of $0.90 and a 1 year high of $2.70.

An institutional investor recently bought a new position in CounterPath stock. Wedbush Securities Inc. purchased a new stake in CounterPath, Corp. (NASDAQ:CPAH) (TSE:CCV) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 26,000 shares of the software maker’s stock, valued at approximately $43,000. Wedbush Securities Inc. owned 0.44% of CounterPath as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.61% of the company’s stock.

CounterPath Company Profile

CounterPath Corporation designs, develops, and sells software and services that enable enterprises and telecommunication service providers to deliver unified communications services over Internet protocol based networks in North America and internationally. Its products include Bria softphone suite, which enables consumers and business users to make voice over Internet protocol (VoIP) audio and video calls, send instant messages, manage their presence, share their screen, and collaborate with other users using desktop computers and laptops, smartphones, and tablets; and X-Lite, a standards-based VoIP softphone application that runs on desktop computers.

Further Reading: How to Invest in the Dividend Aristocrat Index

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for CounterPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CounterPath and related companies with's FREE daily email newsletter.